WILLIAMSVILLE, N.Y., March 03, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company that is focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, announced today that it has secured an exclusive agreement with CannaMetrix, LLC ™ for the use of their proprietary, human cell-based testing...Read More